Sector Expert: John Vandermosten

Zacks Small-Cap Research



Recent Quotes

"PMN anticipates launching its first in-human trial in 2019 of PMN310."

— John Vandermosten, Zacks Small-Cap Research (8/22/18)
more >

"We are initiating coverage on PMN."

— John Vandermosten, Zacks Small-Cap Research (6/27/18)
more >

"RXII's sd-rxRNA can augment already amazing results in immunotherapy."

— John Vandermosten, Zacks Small-Cap Research (12/7/17)
more >

"RXII expects to announce data from its clinical trials later this year and in early 2018."

— John Vandermosten, Zacks Equity Research (9/25/17)
more >

"At the current price, we view RVX shares as undervalued, and in a position to provide long-term upside potential

— John Vandermosten, Zacks Equity Research (8/2/17)
more >

"We view RVX's shares as undervalued, and in a position to provide long-term upside potential."

— John Vandermosten, Zacks Equity Research (6/14/17)
more >

"Our investment thesis for RVX is based on a large and growing underserved market in cardiovascular disease."

— John Vandermosten, Zacks Equity Research (3/30/17)
more >

— John Vandermosten, Zacks Equity Research (12/16/16)
more >

more comments

"RVX has identified six different pathways where apabetalone has shown promise in improving MACE."

— John Vandermosten, Zacks Equity Research (10/17/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.